Enanta製藥 ENTA 深 滬
等待開盤 09-16 09:30:00 美东时间
7.46
-0.820
-9.90%
華盛通- 最 高8.35
- 今 開8.32
- 成交量 40.09万股
- 最 低 7.28
- 昨 收 8.28
- 總市值 1.59亿
- 52周最高 13.3699
- 市盈率 靜 --
- 換手率 1.88%
- 52周最低 4.09
- 委 比 73.72%
- 總股本 2137.66万
- 歷史最高 127.77
- 量 比 2.38
- 振 幅 12.92%
- 歷史最低 4.09
- 每 手 1
- 風險率 2.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多4 Analysts Have This To Say About Enanta Pharma
Providing a diverse range of perspectives from bullish to bearish, 4 analysts h...
09-15 22:01
Evercore ISI Group Maintains Outperform on Enanta Pharma, Lowers Price Target to $12
Evercore ISI Group analyst Liisa Bayko maintains Enanta Pharma (NASDAQ:ENTA) with a Outperform and lowers the price target from $20 to $12.
09-15 21:50
For The FY 2025, Broadwind Expects Revenues In A Range Of $145M To $155M
CICERO, Ill., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Broadwind (NASDAQ:BWEN, or the "Company"))), a diversified precision manufacturer of specialized components and equipment serving global markets, today announced the
09-11 04:22
IP创新引爆市场，玩模乐器品牌错位竞争｜世研消费指数品牌榜Vol.66
本次监测周期内，乐高、雅马哈和万代分别以1.94、1.65和1.41的综合热度位列榜单前三名。 图源：世研大消费指数 IP创作与授权仍是玩模品牌创新核心，场景...
09-08 10:38
WestPark Capital Initiates Coverage On Enanta Pharma with Buy Rating, Announces Price Target of $24
WestPark Capital analyst Ed Arce initiates coverage on Enanta Pharma (NASDAQ:ENTA) with a Buy rating and announces Price Target of $24.
09-02 19:26
Enanta Pharmaceuticals Appoints Harry R. Trout As Interim Principal Financial Officer
- SEC Filing
08-28 05:01
北大女博士罕见发声：11年前买了贵州茅台20万元，到现在能赚了多少？从贫穷到富有全过程
（来源：A股荟萃） 目前A股市场上最贵的股票非茅台莫属了，而且茅台的股价在“A股最贵”的这个位置上可以说是经久不衰。虽然曾经也有过不少上市公司的股票价格超过茅台...
08-27 16:23
Enanta Sues Pfizer in European Court Over Patent Linked to COVID Drug Paxlovid
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit
08-20 19:08
CISCO REPORTS FOURTH QUARTER AND FISCAL YEAR 2025 EARNINGS
SAN JOSE, Calif., Aug. 13, 2025 /PRNewswire/ -- News Summary: Strong topline performance at the high end of our guidance ranges: Q4 revenue of $14.7 billion, up 8% year over year FY 2025 re...
08-14 04:05
JMP Securities Maintains Market Outperform on Enanta Pharma, Raises Price Target to $25
JMP Securities analyst Roy Buchanan maintains Enanta Pharma (NASDAQ:ENTA) with a Market Outperform and raises the price target from $24 to $25.
08-12 21:02
